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INTRODUCTION
Despite of great advances in early diagnosis and logical
discovery of chemotherapy for cancer and of substantial ad-
vances in molecular oncology, the cure rate of most cancers
remain still low. Primary cancer prevention, particularly che-
moprevention, could become an increasingly useful strategy
in the fight against cancer (1). Fifty years have passed since
the first chemotherapeutic alkylating agent was developed,
and more than a hundred clinical chemotherapeutic regimens
have been developed (2, 3). Nevertheless, the total number
of new cancer patients worldwide in 1985 was estimated to
be 7.62 million (4). The failure to improve the 5-yr observed
survival from 1 in 3 in the 1960s to 1 in 2 in the 1970s stim-
ulated awareness of the importance of primary prevention in
cancer; chemoprevention (5). Since 1977, researchers in Korea
have been trying to discover non-toxic cancer chemopreven-
tive agents from natural food products, including ginseng (6).
LONG-TERM ANTICARCINOGENICITY 
EXPERIMENT
It is hypothesized that the life-prolongation effect of gin-
seng described by Shennong (7) may be due to ginseng’ s effi-
cacy in preventing development of cancers. Therefore, an
investigation was carried out in 1978 to evaluate the effects
of ginseng on the inhibition or prevention of carcinogenesis
induced by various chemical carcinogens. Red ginseng (Fig.
1) extract (1 mg/mL of drinking water) was administered
orally to the weaned mice, and chemical carcinogens, 9, 10-
demethyl-1, 2-benzanthracene (DMBA, 30  g), urethane
(1 mg), N-2 fluorenylacetamide (FAA, 100  g×5), aflatox-
in B1 (8  g), or Hansando tobacco smoke condensates (320
g) were also injected into the subscapular region of ICR
mice within 24 hr after birth. Controls were comprised of
three groups of ICR newborn mice: normal (100), ginseng
(200), and vehicle (316). The ten experimental groups were
Taik-Koo Yun, Yun-Sil Lee,
You Hui Lee*, Shin Il Kim*
Hyo Yung Yun
�
Laboratory of Experimental Pathology, Korea 
Cancer Center Hospital, Seoul; Korea Ginseng &
Tobacco Research Institute*, Taejon; Department
of Surgery, College of Medicine
� , Chungbuk 
National University Hospital, Cheongju, Korea
Address for correspondence
Taik-Koo Yun, M.D.
Laboratory of Experimental Pathology, Korea 
Cancer Center Hospital, 215-4 Gongneung-dong,
Nowon-ku, Seoul 139-706, Korea
Tel : +82.2-335-1020, Fax : +82.2-335-1020
E-mail : tkyun@nuri.net
S6
J Korean Med Sci 2001; 16(Suppl): S6-18
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Anticarcinogenic Effect of Panax ginseng C.A. Meyer and 
Identification of Active Compounds 
The failure to improve the five-year survival rate of cancer patients, from one in
three in the 1960s to one in two in the 1970s, stimulated awareness of the impor-
tance of primary prevention of cancer. Korean investigators carried out extensive
long-term anticarcinogenicity experiments with 2000 newborn mice to investigate
whether Panax ginseng C.A. Meyer inhibited carcinogenesis induced by several
chemical carcinogens in 1978. There was a 22% decrease (p<0.05) in the inci-
dence of urethane induced lung adenoma by the combined use of red ginseng
extract. In the group sacrificed at 56 weeks after the treatment with aflatoxin B1,
the incidence of hepatoma significantly decreased to 75% by the addition of red
ginseng extract (p<0.05). The result showed that natural products can provide
hope for human cancer prevention. By the newly established  ‘9 week medium-
term anticarcinogenicity test model of lung tumors in mice’ (Yun’ s model), we
confirmed significant anticarcinogenic effects of powders and extracts of the 6-
yr-old dried fresh ginseng, 5- and 6-yr old white ginsengs, and 4-, 5-, and 6-yr
old red ginseng. We also demonstrated that the anticarcinogencity of ginseng
was more prominent in aged or heat treated extracts of ginseng and red ginseng
made by steaming. To investigate the active components for cancer prevention,
several fractions of 6-yr old fresh ginseng and red ginseng, four semi-synthetic
ginsenoside Rh1, Rh2, Rg3 and Rg5, major saponin components in red ginseng,
were prepared. Among the ginsenosides, Rg3 and Rg5 showed statistically sig-
nificant reduction of lung tumor incidence and Rh2 had a tendency of decreasing
the incidence. Ginsenoside Rg3, Rg5 and Rh2 were found to be active anticar-
cinogenic compounds. Rg3, Rg5 and Rh2 are active components in red ginseng,
and they prevent cancer either singularly or synergistically.
Key Words : Panax ginseng C.A. Meyer; Long-term Anticarcinogenicity Mouse Model; Chemopreven-
tion; Medium-term Anticarcinogenicity Mouse Model (Yun’ s Model); Active Ginsenoside Components comprised of DMBA (101), DMBA combined with ginseng
(103), urethane (94), urethane combined with ginseng (92),
FAA (90), FAA combined with ginseng (88), aflatoxin B1
(50), aflatoxin B1 combined with ginseng (47) (Table 1). In
the N-methyl-N′ -nitro-N-nitrosoguanidine (MNNG) group,
MNNG (3 mg) was injected subcutaneously into the backs
of Wistar rats once a week for 10 weeks (6, 8). The mice and
rats were autopsied immediately after sacrifice. All major
organs were grossly examined and weighed, and histopatho-
logical examinations were also made. In the group sacrificed
at 48 weeks after the treatment with DMBA (DMBA com-
bined with ginseng), the incidence of diffuse infiltration of
pulmonary adenoma decreased by 61% (p<0.01), and the aver-
age lung weight of male mice decreased by 21% (p<0.05). In
the group sacrificed at 28 weeks after the treatment with ure-
thane, there was 22% decrease (p< 0.05) in the incidence of
lung adenoma by the combined treatment with ginseng. In
the group sacrificed at 56 weeks after treatment with afla-
toxin B1, there was decrease in the incidence of lung adeno-
ma (29%) and hepatoma (75%) (p< 0.05) by the combined
treatment with ginseng (Table 2). In the groups sacrificed
at 68 weeks after the treatment with FAA or 48 weeks of
tobacco smoke condensate treatment, statistically no signifi-
cant decrease was observed. In the group sacrificed at 27 weeks
after treatment with MNNG, ginseng extract had no effect
on the incidence of MNNG-induced sarcoma by the com-
bined treatment with ginseng. These findings indicated that
prolonged administration of red ginseng extract inhibited
the incidence and also the proliferation of tumors induced by
DMBA, urethane, or aflatoxin B1 (6, 8), providing the hope
for human cancer prevention by natural products in human. 
ESTABLISHMENT OF 9 WEEK MEDIUM-TERM
ANTICARCINOGENICITY TEST MODEL 
(YUN’ S MODEL)
Soon after obtaining results of long-term experiments, we
realized that it was necessary to develop a medium-term
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Carcinogens or vehicles Sacrificed after birth (wk)  Dose and route Vehicle
No. of mice
injected
No. of mice  at
weaning
%
1% gelatin 28 and 68 0.02 mL×1 s.c. H2O 199 194 97.5
DMSO 56 0.01 mL×1 s.c. 200 192 96.0
DMBA 26 and 48 30  g×1 s.c. 1% gelatin  210 204 97.1
Urethane 28 and 50 1 mg×1 s.c. 1% gelatin 200 186 93.0
FAA 25 and 68 100  g×5 s.c. 1% gelatin 201 178 88.6
Aflatoxin B1 56 8  g×1 s.c. DMSO 200 104 52.0
Tobacco smoke
condensate 67 320 g×1 s.c. 1% gelatin 200
Table 1. Survival of ICR newborn mice injected with various chemical carcinogens at weaning in long-term anticarcinogenicity
experiment
DMSO: Dimethylsulfoxide, FAA: N-2- Fluorenylacetamide, DMBA: 9, 10-Dimethyl-1, 2-benz(a)anthracene.
Sacrifice (wks) Weight of lung
Incidence of
lung adenoma
Diffuse infiltration Incidence of hepatoma
DMBA 48 21% decrease - 63% decrease -
Urethane 28 - 22% decrease*
Aflatoxin B1 56  - 29% decrease - 75% decrease*
Table 2. Effect of red ginseng extract on pulmonary adenoma induced by various chemical carcinogens in long-term in vivo experi-
ments
DMBA: 9,10-dimethyl-1,2-benzanthracene. *: p<0.05
Fig. 1. Panax ginseng C.A. Meyer in Korea are classified into
fresh ginseng (left), white ginseng (center) and red ginseng
(right).model for further experiments to eliminate the fluctuation
of experimental conditions due to long-term feeding, and to
include synthetic environmental chemical carcinogens such
as ben30(a)pyrene (BP). Therefore, in 1983, we embarked
to establish a 9-12 weeks medium-term anticarcinogenicity
test model (9). A/J, C57BL/6J, C57BR/cdJ and N:GP(S)
strains of newborn mice younger than 24 hr old were inject-
ed subcutaneously with 0.5 mg or 1 mg of BP and all mice
were sacrificed at the 9th week after birth. Lungs were excised
and fixed in Tellyesniczky’ s solution (100 mL of 70% ethanol,
3 mL of formalin, 5 mL of glacial acetic acid), and the num-
ber of the adenoma were than counted by the naked eyes
(Fig. 2). After counting, the lungs were embedded in paraf-
fin, cut and then stained with hematoxylineosin. To obtain
an index of tumor incidence, the percentage of tumor bear-
ing mice per total number of mice in each group was calcu-
lated. Tumor multiplicity was defined as the average num-
ber of tumors per mouse obtained, by dividing the total num-
ber of tumors by the total number of mice per group includ-
ing nontumor-bearing animals. Statistical comparison was
then made using the Chi-square test for tumor incidence and
Student’ s t-test for multiplicity. Lung adenoma incidence
was 46.8% and 54.4% in N:GP(S) mice treated with 0.5 mg
and 1 mg of BP, respectively. Corresponding values of A/J
mice were 86.7% and 88.3%, those of C57BL/6J mice were
1.3% and 0%, and those of C57BR/ cdJ were 0%. The dose
response effect of BP in A/J and N:GP(S) mice were also ex-
amined: A single injection of 40  g of BP, which was the
lowest dose in this experiment, showed 71.0% incidence of
lung adenoma in A/J mice, which might be too high inci-
dence for evaluating the anticarcinogenicity of unknown com-
pounds. However, the dose showing a 50% tumor incidence
in N:GP(S) mice was found to be 0.5 mg of BP (49.4%)
(9-12). In 1983, we established a 9 week medium-term anti-
carcinogenicity model, termed Yun’ s model, based on the
incidence of N:GP(S) mouse pulmonary adenomas induced
by benzo(a) pyrene.
MATERIALS AND METHODS OF YUN’ S MODEL
N:GP(S) newborn mice less than 24 hr old were subcuta-
neously injected once in the scapular region with 0.02 mL
of benzo(a)pyrene (0.5 mg suspension of BP in aqueous
gelatin). After weaning, test materials were administered
for 6 weeks through drinking water or diets. All mice were
sacrificed at the 9th week after birth. The procedures to
score the index of lung tumor incidence were the same as
those described under  “Establishment of 9 week medium-
term anticarcinogenicity test model (Yun’ s model)” (9-12).
EVALUATION OF YUN’ S MODEL
Ascorbic acid,  -carotene, red ginseng extract (6 yr old),
carrot, soybean lecithin, spinach, Sesamum indicum, Ganoder-
ma lucidum, caffeine, capsaicin (13-15), fresh ginseng (4 yr
old), biochanin A (16) and 2-allylthiopyrazine (17, 18) were
evaluated as anticarcinogenic agents, using the above 9 week
medium-term test model. Surprisingly, the authors failed to
observe any anticarcinogenic effect of  -carotene, fresh gin-
seng, carrot, Sesamum indicum, spinach, however, ascorbic acid,
red ginseng extract, soybean lecithin, Ganoderma lucidum,
caffeine, capsaicin and 2-allylthiopyrazine showed positive
effects (10-12, 19). This result was withheld for publication
for 5 yr due to the unexplainability of the data (9). Soon after,
the preliminary reports of the Physician’ s Health Study in
U.S.A. appeared to indicate negative results with  -carotene
(20). Similar results of lack of efficacy were also observed in
an ATBC trial using 29,133 randomly selected male smok-
ers (21), a CARET trial studying more than 18,000 people
at high risk of lung cancer (22, 23), and a Physicians’ Health
Study which enrolled 22,071 American physicians (24). At
the recommendation of the Chemoprevention Branch, Divi-
sion of Cancer Chemoprevention and Control, US National
Cancer Institute (25, 26), researchers in Korea tested the effect
of red ginseng extract on azoxymethane (AOM)-induced
colon cancer and N-butyl-N-(4-hydroxybutyl)-nitrosamine
(OH-BBN)-induced bladder cancer, and the result were neg-
ative (unpublished). Moreover, 13-cis retinoic acid was also
without benefit in the 9-week medium-term study (12, 19,
27) (Table 3).
Recently, the loci responsible for mouse lung tumor sus-
ceptibility have been mapped to chromosomes 6, 9, 17, and
19, while those linked to lung tumor resistance have been
mapped to chromosome 4, 11, 12, and 18. Known candi-
date genes for susceptibility or resistance include the K-ras
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Fig. 2. Gross appearance of mouse lung with adenomas. Mouse
was given a single subcutaneous injection of benzo(a)pyrene
within 24 hr after birth and killed 9 weeks after birth.proto-oncogene on chromosome 6, and the p16 tumor supres-
sor gene on chromosome 4. The mouse lung tumor model
has been expanded by various researchers including the
Chemoprevention Branch of the NCI to include preclinical
screening of chemopreventive agents against human lung
cancer (28). Furthermore, this model system was also em-
ployed to confirm the negative anticarcinogenicity effect of
9-cis retinoic acid, 4-HPR and oltipratz that had been known
as promising cancer preventive agents in the NCI recom-
mended model (29).
ANTICARCINOGENICITY OF TYPES AND AGES
OF PANAX GINSENG C.A. MEYER
Using Yun’ s model, investigators earlier confirmed the
anticarcinogenic effect of 6-yr-old red ginseng extract. In
this model, we further investigated the anticarcinogenic
effects of fresh or white ginsengs and their derivatives, and
the dependency of their anticarcinogenic effects on types
and ages of ginseng derivatives. Here, fresh ginseng of 1.5,
3, 4, 5, and 6 yr of age (Fig. 3) was dried at room tempera-
ture, finely powdered, and extracted 3 times in a water bath
for 8 hr (yield of extract: 45%). White ginseng was also
processed in the same way as fresh ginseng after removal of
its cortex and fine root (yield of extract: 47%). For prepara-
tion of red ginseng, fresh ginseng was steamed, dried, and
processed in the same way as fresh ginseng (yield of extract:
51%). Overall, dried fresh ginseng, red ginseng powders or
extracts of 1.5, 3, 4, 5, and 6 yr of age, and white ginseng
powders or extracts of 3, 4, 5, and 6 yr of age were used.
These preparations at 5 mg/mL were orally administered at
the weaning, and all the mice were sacrificed at the 9th week.
The following results were obtained: 1) the incidence of BP-
induced lung adenoma was 41.3%, however, its incidence
was reduced in the group treated with the dried fresh gin-
seng powder. The incidence of lung adenoma induced by BP
was reduced to 31.2%, 30.0%, 31.3%, 30.3 and 27.8%
(p<0.05) after co-treatment with 1.5-, 3-, 4-, 5-, and 6-yr-
old dried fresh ginseng powders, respectively. Thus, a statis-
tically significant effect was observed only when treated with
6-yr-old dried fresh ginseng powder. 2) the incidence of BP-
induced lung adenoma was 45.0% and its incidence decreased
to 41.3%, 38.0%, 31.6% (p<0.05), and 25.3% (p<0.05)
after co-treatment with 3-, 4-, 5-, and 6-yr-old white gin-
seng powders, respectively. Thus, anticarcinogenic effects
were observed with 5- and 6-yr-old white ginseng powders.
3) the incidence of lung adenoma was 48.6% in the control
group, and its incidence diminished to 37.9%, 41.7%, 31.7%
(p<0.05), 28.3% (p<0.05), and 25.4% (p<0.01) after co-
treatment with 1.5-, 3-, 4-, 5-, and 6-yr-old red ginseng
powders, respectively. Therefore, anticarcinogenic effect was
prominent in 4-, 5-, and 6-yr-old red ginseng powders (30).
Simultaneously, each ginseng powders of various types and
ages were extracted and these extracts (2.5 mg/mL) were
orally administered. All the mice were sacrificed at the 9th
week, and the following results were obtained: the incidence
of BP induced lung adenoma was 63.9% in the control group
for the dried fresh ginseng extract treated group, and its inci-
dence was reduced to 48.3%, 52.5%, 51.8%, 47.5%, and
44.1% (p<0.05) after cotreatment with 1.5-, 3-, 4-, 5-, and
6-yr-old dried fresh ginseng, respectively. Statistical signifi-
cance was observed only in 6-yr-old dried fresh ginseng ex-
tract. The incidence of lung adenoma induced by BP in the
control group was 41.3% and were 31.0% 46.0%, 44.0%,
and 26.5% (p<0.05) after co-treatment with 3-, 4-, 5-, and
6-yr-old white ginseng extracts, respectively, showing sta-
tistically significant effect with 6-yr-old white ginseng ex-
tract. In the control group, the incidence of lung adenoma
induced by BP was 47.5% and its incidence diminished to
40.7%, 35.0%, 30.1% (p<0.05), 30.0% (p<0.05), and
26.3% (p<0.05) after co-treatment with 1.5-, 3-, 4-, 5-, and
6-yr-old red ginseng extract, respectively, thereby showing
the statistically significant anticarcinogenic effects in 4-, 5-,
and 6-yr-old red ginseng extracts. From these results, we con-
cluded that significant anticarcinogenic effect was observed in
extracts of 6-yr-old dried fresh ginseng, 6-yr-old white gin-
seng, and 4-, 5-, and 6-yr-old red ginseng. The results also
demonstrated that the anticarcinogenicity of ginseng was
more prominent in aged or heat treated extracts of fresh
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Anticarcinogenicity
Negative Positive
Carrot
(28) Ascorbic acid
(27)
Fresh ginseng (4 yr old)
(28) Soybean lecithin
(28)
Spinach
(28) Ganoderma lucidum
(28)
-Carotene
(28) Red ginseng extract (6 yr)
(28)
Sesamum indicum
(28) Caffeine
(28)
13-cis retinoic acid
(30) Capsaicin
(33)
French wine
(37) Biochanin A
(45)
Refined rice wine
(37) 2- Allylthiopyrazine
(37)
Authentic honey
(37)
Table 3. Evaluation of anticarcinogenicity using Yun’ s 9 week
medium-term anticarcinogenicity model
Fig. 3. Fresh state of Panax ginseng C.A. Meyer at 1.5, 3, 4, 5,
and 6 yr.
1.5 yr 
(140 g)
3 yr 
(140 g)
4 yr 
(140 g)
5 yr 
(140 g)
6 yr 
(140 g)ginseng and red ginseng prepared by steaming (30-32)
(Table 4). 
SUPPORTIVE ANTICARCINOGENIC EFFECTS
OF PANAX GINSENG C.A. MEYER IN VARIOUS
MODELS IN VITRO AND IN VIVO
In a study on the development of rat liver cancer induced
by diethylnitrosamine, only one out of seven rats given red
giseng developed a tumor, whereas all of the six control rats
succumbed to tumor (33). Tissue-culture biomass tincture
obtained from cultured Panax ginseng cells has a strong in-
hibitory effect on the development of rat mammary adeno-
carcinoma induced by methyl-N-nitrosourea administration
(34) and experimental uterine cervix and vaginal tumors (35).
Red ginseng extracts had a significant inhibitory effect on
skin cancer formation in a two-stage carcinogenesis mouse
model: red ginseng extract at 50-400 mg/kg inhibited the
development of skin papillomas induced by DMBA and
croton oil in mice, decreased in the incidence, prolonged the
latent period before tumor occurrence, and reduced tumor
number per mouse in a dose-dependent manner (36). 12-o-
tetradecanoylphorbol-13-acetate (TPA)-induced production
of tumor necrosis factor in mouse skin was inhibited by
methanol extract of heat-processed neoginseng (37). Dietary
administration of red ginseng powder in the initiation stage
of carcinogenesis in the colon of rats suppressed preneoplas-
tic lesions induced by 1,2-dimethylhydrazine; this effect
was associated with suppression of cell proliferation (38). 
It should be noted here that Chinese (33, 36), Russian (34,
35), Korean (37) and Japanese (38) scientists only recently
began to concentrate their effort on the cancer-preventive
rather than the general effects of ginseng.
CONSTITUENTS OF PANAX GINSENG C.A.
MEYER CULTIVATED IN KOREA
The presence of saponin in ginseng was first reported by
Garriques in 1854 (39), when he isolated a saponin compo-
nent from American ginseng, Panax quinquefolius and named it
“Panaquilon” . In 1957, Brekhman et al. reported saponin
as the active component of ginseng (40). In 1965 the Shiba-
ta and Tanaka’ s group reported that ginseng saponin was
triterpenoidal glycosides of dammarane type with glucose,
arabinose, xylose or rhamnose, and named them ginseno-
side-Rx as active components (41). Wu et al. also isolated  -
pyrrolidone, an artifact of ginseng alkaloids extract isolated
and found to suppresss the growth rate of HeLa and KB
cells in 1969 (42). Thirty-five kinds of ginsenosides have so
far been isolated from fresh, white or red ginseng, among
which 22 kinds of ginsenosides are protopanaxadiol type,
and 12 of them are protopanaxatriol type, and one ginseno-
side Ro is oleanane type. Since ginsenosides are generally
labile under acidic conditions, ordinary acidic hydrolysis is
always accompanied by many side reactions such as cycliza-
tion of side chains, glycosyl elimination and epimerization
of carbone-20 by SN1 reaction. Therefore, the chemical trans-
formations of secondary metabolites occur during steaming
process to prepare red ginseng. The unique components of
red ginseng are known as 20(S)-ginsenoside Rg3 (43), gin-
senosides Rh2 (43), Rs1, or Rs2, Rs3, Rs4 (44) and Rg5 (45),
plus notoginsenoside-R4 in protopanaxadiol group, and 20
(R)-ginsenoside Rg2 (46), 20(R)-ginsenoside-Rh1, ginseno-
side Rh4 and F4 (47) in protopanaxatriol group. Malonyl-
ginsenoside-Rb1, -Rb2, -Rc, and Rd are found only in white
ginseng (48). Among chemical constituents other than
saponin, 1-2% ether soluble components are present in the
root of ginseng. Twelve kinds of phenolic compounds, includ-
ing salicylic acid, caffeic acid, and maltol, have been isolated
from ginseng. Especially, maltol which is present only in
red ginseng and produced from maltose by amino-carbonyl
reaction, shows antioxidant activity. Nine kinds of poly-
acetylene compounds have been isolated and characterized
as pananaxynol, panaxydol, panaxytriol, acetylpanaxydol,
chloropapaxydol, and panaxyne, and also ginsenoyne A, B,
C, D, E, F, G, H, I, J, K from hexane-soluble fraction have
been reported. As for essential oils, about 30 kinds of ses-
quiterpenes including azulene and patchoulene have been
S10 T.-K. Yun, Y.-S. Lee, Y.H. Lee, et al.
Experimental groups
Incidence of lung adenoma
Fresh ginseng White ginseng Red ginseng
Powder Powder Extract Extract Powder Extract
Benzo(a)yrene (BP) 41.3 63.9 45.0 41.3 48.6 47.5
BP+1.5 yr 31.2 48.3 -- -- 37.9 40.7
BP+3 30.0 52.5 41.3 32.0 41.7 35.0
BP+4 31.3 51.8 38.0 46.0 31.7* 30.1*
BP+5 30.3 47.5 31.6* 44.0 28.3
� 30.0*
BP+6 27.8* 44.1* 25.3
� 26.5* 25.4
� 26.3*
Table 4. Anticarcinogenic effects of Panax ginseng C.A. Meyer according to type and age; using Yun’ s 9 week medium-term anti-
carcinogenicity model
BP: Benzo(a)pyrene, Years: Age of ginseng at harvest. *: p<0.05, 
� : p<0.02 and 
� : p<0.01.identified from the ether soluble fraction of fresh ginseng,
and five kinds of methoxypyrazine and eight kinds of al-
kypyrazine derivatives have been identified from the basic
fraction of the ether-soluble extract. Sesquiterpene alcohol,
panasinsanols A and B, have also been isolated. Seven kinds
of  -caboline alkaloid have been isolated from the ether-sol-
uble alkaloidal fraction, and choline has been isolated from
the water soluble fraction. Twenty-one kinds of neutral or
acidic polysaccharides which make up 50-60% of the gin-
seng root have been purified and named panaxan A-U con-
sisting of glucose, arabinose, galactose, rhamnose, xylose or
uronic acid. Ginseng contains 12 to 15% of nitrogen con-
taining compounds, which are comprised of amino acids,
adenosine, and pyroglutamic acid, and Arg-Fru-Glc is formed
by amino-carbonyl reaction during the preparation of red
ginseng. Other vitamins, inorganic substances, free monosac-
charides, and organic acids are also present in ginseng (49).
ANTICARCINOGENICITY OF VARIOUS GINSENG
FRACTIONS
Ginseng has been taken as tonic for a long time in Korea.
Therefore, instead of examining its active fractions or com-
ponents, we focussed our study to confirm whether ginseng
has an effective anticarcinogenic agent in humans as it has
been shown in rodents for more than 15 yr.
To identify its active fractions, several extracts of red and
fresh ginseng were tested for anticarcinogenicity using Yun’ s
9 week medium model. For fractionation of red ginseng,
powdered red ginseng (2 kg) of 6 yr old Panax ginseng C.A.
Meyer cultivated in Korea was extracted with water (2 L×2)
at 90℃ and filterd, and one-tenth of the combined filtrates
were evaporated to give a  “water extract” (104 .4 g). Remain-
ing combined filtrates were successsively extracted  with
hexane (1 L×3) and water saturated n-BuOH (700 mL×3),
and dried to give hexane fraction (1.2 g) and named panax-
an A-U consisting of glucose, arabinose, galatose, rhamnose,
xylose or uronic acid. The water layer was also evaporated to
give water fraction (715.9 g). n-BuOH fraction was chro-
matographed on silica gel column, and the gel was eluted
with CHCl3-MeOH-H2O (10:3:1→7:3:1). Eluates were
examined by TLC together with authentic samples, and
panaxadiol type saponin (29.2 g) and panaxatriol type saponin
(32.8 g) were obtained (50, 51).
For fractionation of fresh ginseng, fresh ginseng was air-
dried and powdered. The powdered fresh ginseng (1 kg)
was extracted with water (2 L×2) at 90℃ and filtered. One-
tenth of the combined filtrates were evaporated to give a
water extract (49.2 g), and nine-tenths of the combined fil-
trates were extracted with ethyl ether (1 L×3) and water
saturated n-BuOH (700 mL×3), to give n-BuOH fraction.
The combined n-BuOH fraction were dried and evaporated
under the reduced pressure to give total saponin (63.6 g).
The powdered fresh ginseng (500 g) was extracted with
70% EtOH (1 L×3) at 80℃ and filtered, and the combined
filtrates were then evaporated to give EtOH extract (142.1
g). To obtain polysaccharide fraction from fresh ginseng, the
air-dried and powdered fresh ginseng (1 kg) was defatted
with 85% EtOH (2 L×3), and the residues were extracted
with hot water (1 L×3). The combined extracts were evap-
orated to appropriate volumes and then dialyzed against run-
ning water for 3 days and distilled water for 1 day. After non-
dialyzate portion was centrifuged to remove insoluble mate-
rials, the resulting supernatant was precipitated with 6 vol-
umes of EtOH, and the precipitate was lyophilized to give
polysaccharide fraction (13.3 g) (52).
For the preparation of ginsenoside Rg3 and Rg5 mixture,
the ginsenoside Rb1 (10 g) obtained from Korean ginseng
(10 g) was hydrolyzed with 50% acetic acid (500 mL) at 70℃
for 3 hr. The reaction mixture, concentrated to appropriate
volume, was left at 4℃ for 1 day and filtered. The filtrate
was diluted with water (500 mL) and extracted with n-BuOH
(250 mL×3). The combined n-BuOH fractions were washed
with saturated NaHCO3 solution and evaporated under the
reduced pressure. The residue was chromatographed on silica
gel column, using CHCl3-MeOH-H2O (9:3:1) as solvent, to
obtain ginsenoside Rg3 and Rg5 mixture. Ginsenoside Rg3
and Rg5 mixtures were subjected to HPLC (Waters 244, CLC-
ODS, RI dectector), using acetonitril-water (60:40) as mobile
phase, to analyze the ratio of ginsenoside Rg3 to Rg5 (2.6 g)
(45, 50).
The ginseng fractions were administered to newborn mice
after weaning for 6 weeks: Red ginseng water extract (2 mg/
mL drinking water), hexane fraction (21.9  g/mL), ether frac-
tion (42.3  g/mL), panaxadiol type saponin (67.7  g/mL),
panaxatriol type saponin (56.6  g/mL) or water extract
(811.4  g/mL) in experiment 1; 70% ethanol extract of
fresh ginseng (4.72 mg/mL), total saponin of fresh ginseng
(0.44 mg/mL) and polysaccharide of fresh ginseng (1.32
mg/mL) in experiment 2; ginsenoside Rg3+Rg5 (7:3 ratio,
80  g/mL) in experiment 3. All mice were sacrificed at the
9th week after birth.
Lung adenoma incidence was 46.8% in mice treated with
0.5mg of BP. However, when treated together with red gin-
seng, the incidence significantly reduced to 27.5% (inhibi-
tion rate 36.8%). Panaxadiol type saponin, panaxatriol type
saponin, hexane fraction and water fraction showed 42.3%,
41.3%, 40.0% and 41.3% incidence, respectively, with no
significant reduction observed in experiment 1 (Table 5).
The next step was to compare anticarcinogenicity of 6 yr
fresh ginseng fractions of 70% ethanol extract, water extract,
total saponin and polysaccharide. Lung adenoma incidence
was 58.3% in 0.5 mg of BP alone treated mice. The treat-
ment of ethanol extract and total saponin together with BP
reduced lung tumor incidence significantly to 44.1% (inhibi-
tion rate 25.7%) and 43.3% (inhibition rate 24.4%), respec-
tively, however the incidence of polysaccharide treatment
Anticarcinogenicity of Panax ginseng and Active Components S11was 50.0%, with no significant reduction being observed in
experiment 2 (Table 6).
Experiment 3 was to examine which components of red
ginseng were responsible for anticarcinogenicity. For the
experiment, Rg3 and Rg5 mixtures were selected, because
they are present in large amounts in red ginseng and their
semi-syntheses are possible. Lung adenoma incidence was
60.0% in 0.5 mg of BP alone treated mice, however, the
treatment of Rg3+Rg5 mixture with BP significantly re-
duced the incidence to 45.0% (inhibition rate 25.0%). The
results showed that Rg3+Rg5 had anticarcinogenic effect in
Yun’ s model (50) (Table 7).
Since red ginseng showed the most effective anticarcino-
genicity, semi-synthesized ginsenoside Rg3 and Rg5 mix-
tures were selected for experiment. The results showed sig-
nificant inhibition of lung adenoma in the Yun’ s model, indi-
cating that ginsenoside Rg3 and Rg5, alone or in combina-
tion, would be active anticarcinogenic components. 
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Sex Experimental groups and treatment No. of mice
No. of mice with
lung tumor
Lung tumor 
incidence (%)
Inhibition rates (%)
Benzo(a)pyrene (BP) M 30 16 53.3
0.5 mg/mice S.C. F 30 19 63.3
M+F 60 35 58.3 Reference
BP+70%EtOH extract M 30 11 36.7
4.72 mg/mL D.W. F 30 15 50.0
M+F 60 26 43.3* 25.7
BP+Water extract M 30 13 43.4
6.4 mg/mL D.W. F 29 13 44.8
M+F 59 26 44.1* 24.4
BP+Total saponin M 30 13 43.3
0.44 mg/mL D.W.  F 30 13 43.3
M+F 60 26 43.3* 25.7
BP+Polysaccharide M 30 13 43.3
1.32 mg/mL D.W. F 30 17 56.7
M+F 60 30 50.0 14.2
Table 6. Effects of ethanol extract, water extract, total saponin and polysaccharide isolated from fresh ginseng on the incidence of
benzo(a)pyrene induced lung tumor in mice, using Yun’ s 9 week medium-term anticarcinogenicity test model
D.W.: Drinking water, *: p<0.05
Experiment-2
Sex Experimental groups and treatment No. of mice
No. of mice with
lung tumor
Lung tumor 
incidence (%)
Inhibition rates (%)
Benzo(a)pyrene (BP) M 40 15 37.5
0.5 mg/mice S.C. F 39 22 56.4
M+F 79 37 46.8 Reference
BP+Red ginseng water extract M 40 8 20.0
2 mg/mL D.W. F 40 14 35.0
M+F 80 22 27.5* 36.8
BP+Panaxadiol type saponin M 38 16 42.1
67.7 g/mL D.W. F 40 17 42.5
M+F 78 33 42.3 9.6
BP+Panaxatriol type saponin M 40 16 40.0
56.6 g/mL D.W. F 40 17 42.5
M+F 80 33 41.3 11.8
Bp+Hexane fraction M -- -
21.9 g/mL D.W. F 40 16 40.0
M+F 40 16 40.0 14.6
BP+Water fraction M 40 13 32.5
811.4 g/mL D.W. F 40 20 50.0
M+F 80 33 41.3 11.8
Table 5. Effects of red ginseng water extract, panaxadiol type saponin, panaxatriol type saponin, hexane fraction and water fraction
on the incidence of benzo(a)pyrene induced lung tumor in mice using Yun’ s medium-term test model
D.W.: Drinking water, *: p<0.05
Experiment-1IDENTIFICATION OF ACTIVE ANTICARCINO-
GENIC COMPONENTS IN RED GINSENG
Fresh Panax ginseng C.A. Meyer cultivated in Korea (Kore-
an red ginseng) was reported to be ineffective as anticarcino-
genic or cancer preventive agent both in experimental ani-
mal model and in human case-control and cohort study.
However, when treated with heat, the fresh or white ginseng
and red ginseng were highly effective in cancer prevention.
Consequently, we purified four compounds, 20(S)-ginseno-
side Rhl (Rhl) (54), 20(S)-ginsenoside Rh2 (Rh2) (55), 20(S)-
gisenoside Rg3 (Rg3) and ginsenoside Rg5 (55) from Korean
red ginseng and tested them by Yun’ s model.
Ginsenoside Rg5 was isolated as previously described (45),
and Rg3 and Rh2 were by usual procedure from Korean red
ginseng (51, 55). In brief, a mixture of 20(R)- and 20(S)-
ginsenoside Rg3 was obtained under mild acidic hydrolysis
from protopanaxadiol saponins, ginsenoside Rb1, Rb2, Rc and
Rd. The product was acetylated to give peracetates, which
were further converted into 20(S)-ginsenoside Rg3, 20(R)-
ginsenoside Rg3, 20(S)-ginsenoside Rh2 and 20(R)-ginseno-
side Rh2 by direct alkaline treatment, while Rh1 was pre-
pared from ginsenoside Re by similar procedure (55). All
ginsenosides obtained were identified by physicochemical
and spectral analysis (IR, MASS, 1H, 13C-NMR). Thereafter
N:GP(S) mice were subcutaneously injected once with 0.02
mL of BP suspension (0.5 mg, in l% aqueous gelatin), and
the following ginsenosides were administered in drinking
water (80  g/mL) for 6 weeks; ginsenosides Rh1, Rh2, Rg3
and Rg5 (Fig. 4). Two control groups consisted of normal
animals (no ginseng was given) and red-ginseng adminis-
tered (but no BP-treated). Red ginseng extract (2 mg/mL of
drinking water) was given immediately after weaning. Drink-
ing water was changed every other day and diet was prepared
every other week. At the 9th week after birth, adenomas of
the lung were counted. There was no lung tumor observed
in both normal control mice (no BP administered) and mice
given with ginsenoside Rh1, Rh2, Rg3 or Rg5 alone. However,
60% of lung tumor incidence was found in the group given
once with 0.5 mg of BP. On the other hand, when given with
2 mg of red ginseng extract for 6 week after benzo(a)pyrene
pretreatment, 43.3% of incidence was observed (27.8% de-
crease), which was statistically significant. The incidence of
lung adenoma showed 51.7% in mice treated with ginseno-
side Rh1, indicating no significant effect of Rh1 on the BP-
induced lung tumor. The incidence of lung tumor in mice
treated  with ginsenoside Rh2 and BP showed 48.3% (19.5%
decrease). Although it was not statistically significant, we
considered it to represent  “tendency of decrease” in the inci-
dence.
When given with 80  g/mL concentration for 6 weeks
after BP administration, Rg3 showed statistically significant
decrease (22.2%) in lung tumor incidence (46.7%; p<0.05),
whereas Rg5 and BP had biologically significant incidence
(45.0% and 25.0% decrease) (p<0.05) (Table 8).
Using Yun’ s model, the above results, therefore, demon-
strated that, among the four ginsenosides purified from red
ginseng, Rg3 and Rg5 revealed significant reduction of lung
tumor incidence, while Rh2 had a tendency of decreasing
the incidence, indicating that ginseng is an active cancer
chemopreventive agent (53).
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Sex Experimental groups and treatment No. of mice
No. of mice with
lung tumor
Lung tumor 
incidence (%)
Inhibition rates (%)
Benzo (a) pyrene (BP) M 25 14 56.0
0.5 mg/mice S.C. F 25 16 64.0
M+F 50 30 60.0 Reference
BP+Ginsenoside Rg3+Rg5 M 30 13 43.3
80 g/mL D.W. F 30 14 46.7
M+F 60 27 45.0* 25.0
Table 7. Effects of ginsenoside Rg3+Rg5 mixture on the incidence of benzo(a)pyrene inducecd lung tumor in mice, using Yun’ s 9
week medium-term anticarcinogenicity test model
S.C: Subcutaneous administration, D.W.: Drinking water, *: p<0.05
Experiment-3
Fig. 4. Chemical structure of ginsenoside Rh1, Rh2, Rh3 and
Rg5 GIc-; -D-glucopyranosyl-,  GIc-GIc-; -D-glucopyranosyl
(1�2) -D-glucopyranosyl-.
HO HO
HO
OH OH
O-Glc
HO
HO OH
Glc-GIc-O Glc-GIc-O
Glc-O
20(S)-ginsenoside Rg3 ginsenoside Rg5
20(S)-ginsenoside Rh1 20(S)-ginsenoside Rh2DISCUSSION
As early as the 1960s, alkaloid components of ginseng,  -
pyrrolidone, was reported to inhibit the growth of HeLa cells
(42). Thereafter, saponins have been found to have antimu-
tagenic activity in vitro and in vivo (56); growth inhibitory
activity against several tumor cell lines including nude mouse-
transplantable human colon adenocarcinoma cells (MK-1
cells, mouse melanoma cells (B-16 cells), mouse fibroblast-
derived tumor cells (L929 cells), human colon adenocarci-
noma cells (SW620), human uterus carcinoma cells (HeLa
cells) and human erythroleukemic cells (K562 cells) (57);
growth inhibition of human ovarian cancer cells in nude
mice (58); reverse transformation in cultured Morris hep-
atoma cells (59); induction of differentiation by ginsenoside
in F9 teratocarcinoma cells (60); and immunomodulating
activity of Rg1 in mice (61, 62). The red ginseng was found
to activate natural killer cells in mice with lung adenoma
induced by urethane and benzo(a)pyrene (63). The polysac-
charide revealed anticomplementary activity (64, 65), retic-
uloendothelial system-potentiating activity, alkaline phos-
phatase-inducing activity (66), and cytoprotective activity
(67, 68). Lately, various polyacetylenes extracted from gin-
seng (69, 70) are known to have cytotoxic activity (71).
Ginsenoside Rh1 and Rh2 have recently been reported to
cause differentiation of F9 teratocarcinoma cells, and it has
been suggested that the effects of ginsenosides might have
been exerted via binding with a glucocorticoid receptor or
its analogous nuclear receptor (60). In nude mice bearing
HRA cell tumors, oral administration of Rh2 resulted in a
significant retardation of tumor growth, consequently marked-
ly prolonging survival time (58). The systemic as well as
oral multiple administrations of ginsenoside Rg3 inhibited
lung metastasis produced by Bl6-BL6 melanoma and Colon
26-M3.l carcinoma cells in mice. This antimetastatic effect
was thought to be associated with the inhibition of the inva-
sion and adhesion by tumor cells as well as suppression of
tumor-induced angiogenesis (72-77). These results dealt
mostly with induction of tumor cell differentiation, inhibi-
tion of tumor growths, prolongation of animal survival times
or inhibition of metastasis. Generally, characteristics of the
anticancer effect of ginseng may be summarized as follows:
1) it is observed only in slow-growing tumors such as Ehrlich
and sarcoma 180 ascites tumours in vivo, 2) it is not observed
in rapidly growing tumors such as L1210, P388 ascites
tumors and Walker carcinosarcoma, and 3) there is no dose-
response relationship and no cumulative effect (78-82).
Our strategy now is to switch from therapeutic approaches
to chemoprevention of cancer by identifying effective natu-
ral products. Anticarcinogenic effects of Korean red ginseng
was earlier observed in l980 by long-term (6, 8) or medium
term model (Yun’ s model) (9-12) with mouse lung tumor.
We observed that anticarcinogenicity of ginseng was depen-
dent on the type and age of the ginseng (30, 31). In two
attempts with human case-control studies (83, 84) and a
cohort study (85) to evaluate the cancer preventive effect,
however, fresh ginseng was found to be ineffective to decrease
the relative risk (RR). On the other hand, when treated with
heat, fresh ginseng, white ginseng and red ginseng were sig-
nificantly effective in the decrease of RR, similar to the
results obtained from animal experiments. This result sug-
gested the generation of active cancer chemopreventive com-
pounds of Korean ginseng by heat-treatment.
At present, 35 ginsenosides have been identified in gin-
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Experintal groups 
and treatment
Doses Route Sex No. of mice Incidence
Multiplicity 
(Mean±S.D.)
Normal control M 25 0 0
F2 50 0
M+F5 0 0 0
Benzo(a)pyrene M 25 14 (56.0) 1.20±1.44
BP: 0.5 mg/head S.C. F 25 16 (64.0) 1.80±2.12
M+F 50 30 (60.0) 1.50±1.82
BP+Rh1 M 30 15 (50.0) 1.20±1.54
BP: 0.5 mg/head S.C. F 30 16 (53.3) 1.49±1.86
Rh1: 80  g/mL D.W. M+F 60 31 (51.7) 1.03±1.27
BP+Rh2 M 30 13 (43.3) 0.77±1.14
BP: 0.5 mg/head S.C. F 30  16 (53.3) 1.53±1.93
Rh2: 80  g/mL D.W. M+F 60 29 (48.3) 1.15±1.61
BP+Rg3 M 30 13  (43.3) 0.67±0.96
BP: 0.5 mg/head S.C. F 30 15 (50.0) 1.03±1.27
Rg3: 80  g/mL D.W M+F 60 28 (46.7)* 0.85±1.13
BP+Rg5 M 30 13 (43.3) 0.83±1.21
BP: 0.5 mg/head S.C. F 30 14 (46.7) 1.33±2.89
Rg5: 80  g/mL D.W M+F 60 27 (45.0)* 1.08±2.21
Table 8. Anticarcinogenicity of ginsenosides Rh1, Rh2, Rg3 and Rg5, using Yun’ s 9 week medium-term anticarcinogenicity model 
S.C.: Subcutaneous administration, D.W.: Drinking water, *: p<0.05.seng, and l2 ginsenosides were found in red ginseng (86).
We prepared four ginsenosides from Korean red ginseng
and tested their cancer chemopreventive effect using Yun’ s
model. This model has been successfully employed to con-
firm anticarcinogenicity effect of ginseng on lung tumor
incidence induced by benzo(a)pyrene in mice. Mouse lung
tumor model has been highly recommended for preclinical
as well as clinical test models (28, 29), because this model
showed no anticarcinogenicity with not only  -carotene
and 13-cis retinoic acid (10-12, 19), but also genetic alter-
ation in mouse lung tumor which was similarly to that of
human lung cancer cells.
When taken, 4 yr-old fresh or white ginseng did not show
any anticarcinogenicity in animal model (30, 31), and an
epidemiological study also revealed no statistically signifi-
cant reduction of the relative risk in human (83-85). When
heated, however, these ginsengs were highly effective as anti-
carcinogenic agents and these results were confirmed by
others (33-38). Red ginseng extract in a two-stage carcino-
genesis mouse model had a significant inhibitory effect on
skin cancer formation. At 50-400 mg/kg, red ginseng extract
inhibited DMBA/croton oil-induced skin papillomas in mice,
decreased the incidence, prolonged the latent period before
tumor occurrence, and reduced tumor number per mouse in
a dose-dependent manner (36). Recently, it has been shown
that dietary administration of red ginseng powder in the
initiation stage of carcinogenesis was found to suppress 1,
2-dimethylhydrazine (DMH) induced preneoplastic lesions
in the colon of rats, and that this was associated with sup-
pression of cell proliferation (38).
This fact led to search biologically active components in
ginseng, and they so far identified 35 ginsenosides in gener-
al and l2 in red ginseng (86).
Some of the ginsenosides are present in red ginseng in such
a minute quantity, so that it is extremely difficult to obtain
the amount enough for in vivo assay. Nevertheless, we suc-
ceeded to purify and identify four ginsenosides, including gin-
senoside Rhl, Rh2, Rg3 and Rg5. Among the four ginseno-
sides, Rg3 and Rg5 showed significant reduction of lung
tumor incidence and Rh2 had a tendency of decreasing the
incidence. These results strongly indicate that the anticar-
cinogenicity or human cancer preventive effect of ginseng is
due to ginsenoside Rg3, Rg5 and Rh2.
There has been no report yet on the preventive effect of
ginsenoside Rg3, Rg5 and Rh2 on chemically induced cancer
or spontaneous murine cancer in vivo. Ginsenoside Rg5 was
isolated from methanol extract of Korean red ginseng in 1996
(45), however, there is no report yet on biological activity of
the compound.
Although the mechanism of how these three minor gin-
senosides exhibit the anticarcinogenic effect is not known,
it is highly likely that Rg3, Rg5 and Rh2 in red ginseng pre-
vent cancer either singularly or synergistically, and it is quite
tempting to suggest that the ginsenosides may target one of
the 5 steps of either Vogelstein’ s multi-stage carcinogenesis
or inactivation of suppressor genes (87).
In conclusion, epidemiological studies including case-con-
trol studies (83, 84) and population based cohort study (85)
proved heat-treated red ginseng to be effective non-organ
specific cancer preventive (19, 85, 86, 88, 89). In order to
further confirm these ginsenosides as non-organ specific can-
cer preventive, it is of absolute necessity to chemically syn-
thesize large amounts of the materials for clinical testing as
well.
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